Initiation of four basal insulins and subsequent treatment modification in people treated for type 2 diabetes in the United Kingdom: Changes over the period 2003–2018
Sign Up to like & getrecommendations! Published in 2021 at "Diabetic Medicine"
DOI: 10.1111/dme.14603
Abstract: Aim of this study is to describe changes in the utilization of basal insulins (glargine, detemir, degludec, neutral protamine Hagedorn [NPH]) among individuals with type 2 diabetes between 2003 and 2018 in the United Kingdom… read more here.
Keywords: basal insulins; type diabetes; 2003 2018; united kingdom ... See more keywords
Persistence with Insulin Glargine 300 IU/ml Compared with Other Basal Insulins—A Canadian Retrospective Cohort Study
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes"
DOI: 10.2337/db18-1786-p
Abstract: Introduction: Insulin glargine (300 units/mL) is a long-acting insulin approved in Canada on 28-May-2015 for once-daily administration in the treatment of T1DM or T2DM requiring basal insulin therapy. Made of the identical molecule as insulin… read more here.
Keywords: basal insulins; insulin; insulin glargine; glargine 300 ... See more keywords